文献速递肝肾功能剂量调整药物相互作用

米妥昔单抗索拉夫坦辛在叶酸受体α阳性卵巢癌患者中的群体药代动力学

Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
PubMed 文献 · Br J Clin Pharmacol · 2023-11-13

本研究纳入543例以铂耐药为主的卵巢癌患者,构建半机制群体药代动力学模型描述米妥昔单抗索拉夫坦辛、载荷DM4及代谢物S-甲基-DM4的浓度-时间曲线。体重、血清白蛋白和年龄为显著协变量,但在推荐剂量6 mg/kg(按调整理想体重)下无需因协变量调整剂量。

要点

  • 推荐剂量6 mg/kg(按调整理想体重)下无需因协变量效应调整剂量。
  • 轻中度肾功能不全、轻度肝功能不全无需调整剂量。
  • 合用弱或中度CYP3A4抑制剂无需调整剂量。

核心结论

  • 在推荐剂量6 mg/kg(按调整理想体重)下,无需因协变量效应调整米妥昔单抗索拉夫坦辛剂量。
  • 轻中度肾功能不全、轻度肝功能不全或合用弱/中度CYP3A4抑制剂时无需调整剂量。

研究设计与样本

  • 基于3项临床研究中543例以铂耐药为主的卵巢癌患者,静脉给予0.15至7 mg/kg米妥昔单抗索拉夫坦辛。
  • 采用非线性混合效应建模方法分析血浆药物浓度,并进行逐步协变量建模。

主要发现

  • 建立半机制群体药代动力学模型,包含米妥昔单抗索拉夫坦辛的线性和非线性消除途径及肿瘤细胞内载荷与代谢物的靶腔室。
  • 米妥昔单抗索拉夫坦辛清除率和中央室容积分别为0.0153 L/h和2.63 L。
  • DM4清除率和中央室容积分别为8.83 L/h和3.67 L。
  • S-甲基-DM4清除率和中央室容积分别为2.04 L/h和6.3 L。
  • 体重、血清白蛋白和年龄被确定为具有统计学显著性的协变量。

临床怎么用

  • 临床按推荐剂量6 mg/kg(按调整理想体重)给药时无需因体重、白蛋白或年龄等协变量调整剂量。
  • 轻中度肾功能不全、轻度肝功能不全患者及合用弱/中度CYP3A4抑制剂时无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Mirvetuximab soravtansine is a first-in-class antibody-drug conjugate recently approved for the treatment of folate receptor-α positive ovarian cancer. The aim of this study was to develop a population pharmacokinetic model to describe the concentration-time profiles of mirvetuximab soravtansine, the payload (DM4) and a metabolite (S-methyl-DM4). METHODS: Mirvetuximab soravtansine was administered intravenously from 0.15 to 7 mg/kg to 543 patients with predominantly platinum-resistant ovarian cancer in 3 clinical studies, and the plasma drug concentrations were analysed using a nonlinear mixed-effects modelling approach. Stepwise covariate modelling was performed to identify covariates. RESULTS: We developed a semi-mechanistic population pharmacokinetic model that included linear and nonlinear routes for the elimination of mirvetuximab soravtansine and a target compartment for the formation and disposition of the payload and metabolite in tumour cells. The clearance and volume of the central compartment were 0.0153 L/h and 2.63 L for mirvetuximab soravtansine, 8.83 L/h and 3.67 L for DM4, and 2.04 L/h and 6.3 L for S-methyl-DM4, respectively. Body weight, serum albumin and age were identified as statistically significant covariates. Exposures in patients with renal or hepatic impairment and who used concomitant cytochrome P450 (CYP) 3A4 inhibitors were estimated. CONCLUSION: There is no need for dose adjustment due to covariate effects for mirvetuximab soravtansine administered at the recommended dose of 6 mg/kg based on adjusted ideal body weight. Dose adjustment is not required for patients with mild or moderate renal impairment, mild hepatic impairment, or when concomitant weak and moderate CYP3A4 inhibitors are used.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Tu YP, Hanze E, Zhu F, et al. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite. Br J Clin Pharmacol. 2023. PMID: 37872122. doi:10.1111/bcp.15937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。